NSCLC — Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC
Citation(s)
Alflutinib Versus Alflutinib Plus Chemotherapy for Nonesmall Cell Lung Cancer With EGFR (T790M)- Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-label, Randomised Phase 2 Clinical Trial